Sunday, 16 June 2019

Anti- retrovirus HIV drug Efavirenz receives WHO certification

05 November 2018 | News

Efavirenz is the first drug developed in Thailand and Asean to pass the WHO Pre-qualification Programme.

The World Health Organization (WHO) has certified Thailand Government Pharmaceutical Organization’s anti-retrovirus HIV drug Efavirenz, and the GPO is now looking to overseas sales.

According to GPO chairman Sopon Mekthon, Efavirenz is the first drug developed in Thailand and Asean to pass the WHO Pre-qualification Programme and be included in the WHO’s pre-qualified list. Consequently, international health organizations such as the Global Fund and Unicef can order the medication for use in underdeveloped countries.

The organization had taken 16 years to develop the drug, which has the same properties as the prototype medication. Efavirenz is the medication prescribed to all HIV-infected people when they are first diagnosed with the virus.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Podcast

 

Survey Box

Is Asia becoming the centre of healthcare transformation?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls